Virtual Symposium *NEW*: Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras

ACTIVITY TITLE: Virtual Symposium: Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras

ACTIVITY FORMAT: Virtual Symposium

PROGRAM DESCRIPTION

Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD. In particular, non-steroidal mineralocorticoid receptor antagonists (MRAs) have shown promise in DKD, as demonstrated in recent clinical trial results, and several phase III trials are ongoing.

During this symposium, experts will discuss recent and emerging clinical trial data with MRAs in DKD, particularly non-steroidal MRAs. In addition, they will provide an overview about the underlying pathophysiology, how to identify patients at high-risk, and the current management of DKD.

ESTIMATED TIME TO COMPLETE: 75 minutes

RELEASE DATE: December 26, 2019

EXPIRATION DATE: December 26, 2020

EDUCATIONAL GRANT SUPPORT

This educational activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

INTENDED AUDIENCE

This activity is designed for US-based endocrinologists, cardiologists, lipidologists, diabetologists, gastroenterologists, hepatologists, PAs, registered nurses, and NPs

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Review the association and the pathophysiology between T2D and CKD, and the impact of concomitant CKD and T2D on patient outcomes
• Employ the diagnostic criteria according to evidence-based guidelines for DKD in patients with T2DM at risk for kidney disease progression
• Utilize current treatment options for patients with DKD based on identified benefits and risks, and current guideline recommendations
• Review the efficacy and safety of emerging DKD treatments based on the latest evidence

FACULTY

George L. Bakris, MD (Chair)

• Professor of Medicine
• Director, ASH Comprehensive Hypertension Center
• University of Chicago Medicine
• Chicago, IL

Rajiv Agarwal, MD

• Professor of Medicine
• Indiana University School of Medicine & VA Medical Center
• Indianapolis, IN

Ileana L. Piña, MD, MPH, FAHA, FACC

• Clinical Prof of Medicine, Central Michigan University
• Director CVD Research and Academic Affairs
• Regional and National Director of Heart Failure
• Detroit Medical Center
• Detroit, MI

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

PHARMACIST ACCREDITATION STATEMENT

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19-1024-H01-P

Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

DIETICIAN ACCREDITATION STATEMENT

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activity.

This is a Level II activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Dr. Agarwal discloses the following:

• Royalty: UptoDate
• Consulting Fees: Boehringer, Bayer, Janssen, AstraZeneca, Diamedica Reata, Relypsa, Akebia

Dr. Bakris discloses the following:

• Consulting Fees: Merck, Novo Nordisk, Relypsa, Amgen
• Other: Janssen and Bayer-Steering committee and principal investigator on clinical trials in nephropathy-fees go to U of Chicago

Dr. Piña discloses the following:

• Consulting Fees: Advisory Board – Relypsa, FDA CDRH Reviewer

Planners and Managers

The PIM planners and managers have nothing to disclose.

The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no fees for participating and receiving CME/CE credit for this activity. During the period December 26, 2019 through December 26, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-survey and evaluation. Upon completing, your certificate will be made available immediately.

Media: Internet

For questions about the accreditation of this activity, please visit www.pimed.com.

HARDWARE AND SOFTWARE REQUIREMENTS:

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.